Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis...
11 hours ago
from: Yahoo Finance

Breast cancer, Crofelemer, Jaguar Health, Oncology, Palliative care, Supportive Care in Cancer

More about this

- Jaguar Health announces completed analysis from Phase 3 OnTarget trial
Jaguar Health announced that the recently completed analysis of the prespecified subgroup of adult patients with breast cancer from the...
from: TipRanks

- Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Breakthrough in cancer care: Jaguar Health's crofelemer shows significant improvement for breast cancer patients in Phase 3 trial.
from: Stock Titan